Skip to content

Children receiving Heliox Inhalation in Croup: a randomised controlled trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ISRCTN
Registry ID
ISRCTN82240782
Enrollment
142
Registered
2007-02-22
Start date
2007-03-01
Completion date
Unknown
Last updated
2015-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Croup (laryngotracheobronchitis) Respiratory Croup (laryngotracheobronchitis)

Interventions

Patients will be randomly allocated to receiving ,additionally to the standard croup treatment, either Heliox21 (study group) or Air (control group). Comparison will be made of the primary and second

Sponsors

University Hospitals of Leicester NHS Trust (UK)
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Children, aged six months to five years, presenting to the Emergency Department (ED) with moderate to severe croup (Modified Westley Croup Score of two or more).

Exclusion criteria

Exclusion criteria: 1. Children whose oxygen saturation is less than 95% 2. Children with known pre-existing lung or airway disease, congenital heart disease, or features suggesting other causes of stridor, such as peritonsillar abscess, epiglottitis or inhaled foreign body

Design outcomes

Primary

MeasureTime frame
Modified Westley Croup Score at 30 minutes

Secondary

MeasureTime frame
1. Croup score at 15 minutes 2. Respiratory rate at 15, 30 minutes 3. Parents assessment of change on Visual Analog Scale 4. Number of epinephrine nebulisers given 5. Requirement for supplemental oxygen therapy 6. Admission to hospital 7. Intubation rate 8. Length of stay in ED 9. Length of stay in hospital 10. Subsequent use of health services

Countries

United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026